13.03.2012 18:20 Uhr, Quelle: Presseportal

EANS-News: Intercell AG / Intercell starts a pivotal Phase II/III efficacy study with its Pseudomonas aeruginosa vaccine candidate

Intercell AG: Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Research & Development Wien (euro adhoc) - Vienna (Austria), March 13, 2012 - Today Intercell AG (VSE: ICLL)

Weiterlesen bei Presseportal